论文部分内容阅读
为确立晚期肝癌患者的新的免疫学疗法,作者曾报告过诱导自身癌细胞特异性杀伤T细胞(CTL),并使用此CTL免疫疗法的可能性。作者为研究此疗法的效果,对应用LAK细胞的继承性免疫疗法(LAK细胞疗法)和CTL疗法的效果进行了研究。对12例原发性肝癌(HCC)和4例转移性肝
To establish new immunological therapies for patients with advanced liver cancer, the authors have reported the possibility of inducing autologous cancer cell-specific killer T cells (CTLs) and using this CTL immunotherapy. To study the effect of this therapy, the authors studied the effects of inherited immunotherapy (LAK cell therapy) and CTL therapy using LAK cells. 12 cases of primary liver cancer (HCC) and 4 cases of metastatic liver